Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Intravenous IgG (IVIg) contains polyclonal immunoglobulin G (IgG) from thousands of donors. It is administered at a low dose at regular intervals as antibody replacement therapy and at a higher dose as immunomodulatory treatment in various auto-immune or auto-inflammatory diseases. The working mechanism of immunomodulation is not well understood. Many different explanations have been given. During the last decade, we have focused on classical antibody binding via the Fc-domain of the IgG molecules to the common IgG receptors, i.e. the Fcγ receptors (FcγRs). Variation in the genes encoding human FcγRs determines function as well as expression among immune cells. As described here, NK cells and myeloid cells, including macrophages, can express different FcγR variants, depending on the individual's genotype, copy number variation (CNV), and promoter polymorphisms. B-cells seem to only express the single inhibitory receptor. Although these inhibitory FcγRIIb receptors are also expressed by monocytes, macrophages, and only rarely by NK cells or neutrophils, their presence is unlikely to explain the immunomodulatory capacity of IVIg, nor does the sialylation of IgG. Direct IVIg effects at the level of the activating FcγRs, including the more recently described FcγRIIc, deserve renewed attention to describe IVIg-related immunomodulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of large-scale variation in the human genome
Iafrate, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., Scherer, S. W., & Lee, C. (2004) · Nature Genetics · doi:10.1038/ng1416 · Cited by 2,892
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 1×
“INCREASED CLEARANCE OF PATHOGENIC ANTIBODIES BY SATURATION OF THE NEONATAL FcR FcRn is a receptor expressed by human endothelial cells to recycle plasma IgG, extending its half-life in the circulation (91, 92); saturating this “rescue-receptor” with a high dose of IVIg may shorten the half-life of all IgG including ha…”
The SYK tyrosine kinase: A crucial player in diverse biological functions
Mócsai, A., Ruland, J., & Tybulewicz, V. L. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2765 · Cited by 1,368 · cited 1×
“, those containing or associated with ITAMs, by binding of multivalent ligands, such as an opsonized pathogen or cancer cell, results in the phosphorylation of ITAM tyrosine residues by Src family protein tyrosine kinases (PTKs), and ultimately leads to activation of cellular responses (10).”
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Rice, G. I., Kasher, P. R., Forte, G. M. A., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2414 · Cited by 923
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640 · cited 1×
“INCREASED CLEARANCE OF PATHOGENIC ANTIBODIES BY SATURATION OF THE NEONATAL FcR FcRn is a receptor expressed by human endothelial cells to recycle plasma IgG, extending its half-life in the circulation (91, 92); saturating this “rescue-receptor” with a high dose of IVIg may shorten the half-life of all IgG including ha…”
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura
Debré, M., Griscelli, C., Bonnet, M.-C., Carosella, E., Philippe, N., Reinert, P., Vilmer, E., Kaplan, C., Fridman, W. H., & Teillaud, J.-L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92000-j · Cited by 329
Cited by
Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C. E., Shah, P., Ramnarayan, P., Fraisse, A., Miller, O., Davies, P., et al. (2020) · JAMA · doi:10.1001/jama.2020.10369 · Cited by 1,994
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Zufferey, A., Kapur, R., & Semple, J. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6020016 · Cited by 566
Fc receptors in antibody‐dependent enhancement of viral infections
Taylor, A., Foo, S., Bruzzone, R., Vu Dinh, L., King, N. J. C., & Mahalingam, S. (2015) · Immunological Reviews · doi:10.1111/imr.12367 · Cited by 255
The inflammatory function of human IgA
Hansen, I. S., Baeten, D. L. P., & den Dunnen, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2976-8 · Cited by 170
Peripheral monocytes are functionally altered and invade the CNS in ALS patients
Zondler, L., Müller, K., Khalaji, S., Bliederhäuser, C., Ruf, W. P., Grozdanov, V., Thiemann, M., Fundel-Clemes, K., Freischmidt, A., Holzmann, K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1548-y · Cited by 154
Fajgenbaum, D. C., Langan, R.-A., Japp, A. S., Partridge, H. L., Pierson, S. K., Singh, A., Arenas, D. J., Ruth, J. R., Nabel, C. S., Stone, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126091 · Cited by 147
Wan, J., Weiss, E., Ben Mkaddem, S., Mabire, M., Choinier, P.-M., Picq, O., Thibault-Sogorb, T., Hegde, P., Pishvaie, D., Bens, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8523 · Cited by 77
Metadata
- Authors
- Nagelkerke, S. Q., & Kuijpers, T. W.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-01-21
- Volume
- 5
- Pages
- 674-674
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2085445235
- Cited by
- 139
- References
- 8
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.